Decitabine combined with <scp>RDHAP</scp> regimen in relapsed/refractory diffuse large B cell lymphoma
Xiaoshuang Kong(First Affiliated Hospital of Zhengzhou University), Linan Zhu(First Affiliated Hospital of Zhengzhou University), Xiaolong Wu(First Affiliated Hospital of Zhengzhou University), Mingzhi Zhang(Chinese Academy of Sciences), Xin Li(China Medical University), Xinhua Wang(Zhengzhou University), Meng Dong(First Affiliated Hospital of Zhengzhou University), Lei Zhang(First Affiliated Hospital of Zhengzhou University), Jiaqin Yan(First Affiliated Hospital of Zhengzhou University), Xiaorui Fu(First Affiliated Hospital of Zhengzhou University), Xudong Zhang(First Affiliated Hospital of Zhengzhou University), Ling Li(First Affiliated Hospital of Zhengzhou University), Mengjie Ding(First Affiliated Hospital of Zhengzhou University), Xiaoyan Feng(Academy of Military Medical Sciences), Zhenchang Sun(First Affiliated Hospital of Zhengzhou University), Qingjiang Chen(First Affiliated Hospital of Zhengzhou University)
Cited by 10
Related Papers
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
|Journal of Hematology & Oncology|2016|250
Reversing insufficient photothermal therapy-induced tumor relapse and metastasis by regulating cancer-associated fibroblasts
|Nature Communications|2022|247
Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study
|The Lancet Infectious Diseases|2015|231
miR-137 Is Frequently Down-Regulated in Gastric Cancer and Is a Negative Regulator of Cdc42
|Digestive Diseases and Sciences|2011|140